Marc Piechaczyk

List of Publications by Year
in descending order

98 papers	5,142 citations	94433 37 h-index	95266 68 g-index
103 all docs	103 docs citations	103 times ranked	5267 citing authors

#	Article	IF	Citations
1	Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers. Nucleic Acids Research, 2021, 49, 2488-2508.	14.5	15
2	SUMO and Transcriptional Regulation: The Lessons of Large-Scale Proteomic, Modifomic and Genomic Studies. Molecules, 2021, 26, 828.	3.8	46
3	Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer. Advances in Experimental Medicine and Biology, 2020, 1233, 29-54.	1.6	11
4	Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies. Life Science Alliance, 2020, 3, e201900577.	2.8	13
5	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. Cancer Research, 2019, 79, 5191-5203.	0.9	45
6	The SUMO Pathway in Hematomalignancies and Their Response to Therapies. International Journal of Molecular Sciences, 2019, 20, 3895.	4.1	29
7	AP-1 Signaling by Fra-1 Directly Regulates HMGA1 Oncogene Transcription in Triple-Negative Breast Cancers. Molecular Cancer Research, 2019, 17, 1999-2014.	3.4	15
8	The AP-1 transcriptional complex: Local switch or remote command?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 11-23.	7.4	165
9	Targeting the SUMO Pathway Primes All-<i>trans</i> Retinoic Acidâ€“Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. Cancer Research, 2018, 78, 2601-2613.	0.9	45
10	Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies. JCI Insight, 2018, 3, .	5.0	15
11	Production and Purification of Recombinant SUMOylated Proteins Using Engineered Bacteria. Methods in Molecular Biology, 2016, 1475, 55-65.	0.9	5
12	Detection of Proteinâ€“Protein Interactions and Posttranslational Modifications Using the Proximity Ligation Assay: Application to the Study of the SUMO Pathway. Methods in Molecular Biology, 2016, 1449, 279-290.	0.9	27
13	Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. Emerging Microbes and Infections, 2016, 5, 1-9.	6.5	36
14	c-Fos Protects Neurons Through a Noncanonical Mechanism Involving HDAC3 Interaction: Identification of a 21-Amino Acid Fragment with Neuroprotective Activity. Molecular Neurobiology, 2016, 53, 1165-1180.	4.0	20
15	Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. Trends in Microbiology, 2015, 23, 653-665.	7.7	97
16	Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer. Nucleic Acids Research, 2014, 42, 11011-11024.	14.5	35
17	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Reports, 2014, 7, 1815-1823.	6.4	86
18	Chromatin loop organization of the junb locus in mouse dendritic cells. Nucleic Acids Research, 2013, 41, 8908-8925.	14.5	14

#	Article	IF	Citations
19	Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood, 2013, 121, 1102-1111.	1.4	25
20	An NF-ÎºBâ€“Dependent Role for JunB in the Induction of Proinflammatory Cytokines in LPS-Activated Bone Marrowâ€“Derived Dendritic Cells. PLoS ONE, 2010, 5, e9585.	2.5	30
21	Long-Lasting Protective Antiviral Immunity Induced by Passive Immunotherapies Requires both Neutralizing and Effector Functions of the Administered Monoclonal Antibody. Journal of Virology, 2010, 84, 10169-10181.	3.4	33
22	Heterodimerization with Different Jun Proteins Controls c-Fos Intranuclear Dynamics and Distribution. Journal of Biological Chemistry, 2010, 285, 6552-6562.	3.4	32
23	A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy. PLoS Pathogens, 2010, 6, e1000948.	4.7	50
24	Ubiquitin-independent degradation of proteins by the proteasome. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1786, 153-177.	7.4	128
25	Regulation and function of JunB in cell proliferation. Biochemical Society Transactions, 2008, 36, 864-867.	3.4	65
26	Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: Is there a unique answer?. Biochimie, 2008, 90, 296-305.	2.6	47
27	Endogenous Cytotoxic T-Cell Response Contributes to the Long-Term Antiretroviral Protection Induced by a Short Period of Antibody-Based Immunotherapy of Neonatally Infected Mice. Journal of Virology, 2008, 82, 1339-1349.	3.4	21
28	SUMOylation Regulates the Transcriptional Activity of JunB in T Lymphocytes. Journal of Immunology, 2008, 180, 5983-5990.	0.8	52
29	A Novel Role for PA28Î³-Proteasome in Nuclear Speckle Organization and SR Protein Trafficking. Molecular Biology of the Cell, 2008, 19, 1706-1716.	2.1	63
30	JunB Breakdown in Mid-/Late G₂ Is Required for Down-Regulation of Cyclin A2 Levels and Proper Mitosis. Molecular and Cellular Biology, 2008, 28, 4173-4187.	2.3	22
31	Fos family protein degradation by the proteasome. Biochemical Society Transactions, 2008, 36, 858-863.	3.4	30
32	SUMO under stress. Biochemical Society Transactions, 2008, 36, 874-878.	3.4	154
33	Heterodimerization with Jun Family Members Regulates c-Fos Nucleocytoplasmic Traffic. Journal of Biological Chemistry, 2007, 282, 31046-31059.	3.4	47
34	Ubiquitin-Independent Proteasomal Degradation of Fra-1 Is Antagonized by Erk1/2 Pathway-Mediated Phosphorylation of a Unique C-Terminal Destabilizer. Molecular and Cellular Biology, 2007, 27, 3936-3950.	2.3	86
35	The effects of N-terminal insertion into VSV-G of an scFv peptide. Virology Journal, 2006, 3, 69.	3.4	16
36	Efficient Mother-to-Child Transfer of Antiretroviral Immunity in the Context of Preclinical Monoclonal Antibody-Based Immunotherapy. Journal of Virology, 2006, 80, 10191-10200.	3.4	12

#	Article	IF	Citations
37	Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology, 2005, 332, 418-429.	2.4	27
38	Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?. Critical Reviews in Oncology/Hematology, 2005, 54, 31-51.	4.4	13
39	Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment. Journal of Virology, 2005, 79, 6272-6280.	3.4	25
40	Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation. Molecular and Cellular Biology, 2005, 25, 6964-6979.	2.3	172
41	SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. Journal of Cell Biology, 2004, 165, 767-773.	5.2	89
42	Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genetic Vaccines and Therapy, 2004, 2, 2.	1.5	35
43	Monoclonal Antibody-based Genetic Immunotherapy. Current Gene Therapy, 2004, 4, 347-356.	2.0	12
44	In Vivo Infection of Mice by Replication-Competent MLV-Based Retroviral Vectors. , 2003, 76, 343-352.		3
45	The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene, 2003, 22, 1461-1474.	5.9	60
46	Monoclonal Antibody 667 Recognizes the Variable Region A Motif of the Ecotropic Retrovirus CasBrE Envelope Glycoprotein and Inhibits Env Binding to the Viral Receptor. Journal of Virology, 2003, 77, 10984-10993.	3.4	8
47	c-Fos Proto-Oncoprotein Is Degraded by the Proteasome Independently of Its Own Ubiquitinylation In Vivo. Molecular and Cellular Biology, 2003, 23, 7425-7436.	2.3	65
48	The HBZ Factor of Human T-cell Leukemia Virus Type I Dimerizes with Transcription Factors JunB and c-Jun and Modulates Their Transcriptional Activity. Journal of Biological Chemistry, 2003, 278, 43620-43627.	3.4	180
49	HighIn VivoProduction of a Model Monoclonal Antibody on Adenoviral Gene Transfer. Human Gene Therapy, 2002, 13, 1483-1493.	2.7	34
50	CNF1 Exploits the Ubiquitin-Proteasome Machinery to Restrict Rho GTPase Activation for Bacterial Host Cell Invasion. Cell, 2002, 111, 553-564.	28.9	268
51	The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Research, 2002, 83, 57-69.	2.2	7
52	Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. Biochemical Pharmacology, 2002, 64, 957-961.	4.4	6
53	Skin as a Potential Organ for Ectopic Monoclonal Antibody Production11The authors declared not to have a conflict of interest.. Journal of Investigative Dermatology, 2002, 118, 288-294.	0.7	11
54	Multiple Degradation Pathways for Fos Family Proteins. Annals of the New York Academy of Sciences, 2002, 973, 426-434.	3.8	31

#	Article	IF	Citations
55	Efficient Gene Transfer into Spleen Cells of Newborn Mice by a Replication-Competent Retroviral Vector. Virology, 2002, 293, 328-334.	2.4	13
56	Degradation of cellular and viral Fos proteins. Biochimie, 2001, 83, 357-362.	2.6	11
57	Improvement of Porphyrin Cellular Delivery and Activity by Conjugation to a Carrier Peptide. Bioconjugate Chemistry, 2001, 12, 691-700.	3.6	59
58	Human cyclin C protein is stabilized by its associated kinase cdk8, independently of its catalytic activity. Oncogene, 2001, 20, 551-562.	5.9	38
59	Cellular and viral Fos proteins are degraded by different proteolytic systems. Oncogene, 2001, 20, 942-950.	5.9	13
60	Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G0-to-S phase transition. Oncogene, 2001, 20, 7563-7572.	5.9	38
61	The sensitivity of c-Jun and c-Fos proteins to calpains depends on conformational determinants of the monomers and not on formation of dimers. Biochemical Journal, 2000, 345, 129.	3.7	17
62	The sensitivity of c-Jun and c-Fos proteins to calpains depends on conformational determinants of the monomers and not on formation of dimers. Biochemical Journal, 2000, 345, 129-138.	3.7	38
63	Sustained Systemic Delivery of Monoclonal Antibodies by Genetically Modified Skin Fibroblasts. Journal of Investigative Dermatology, 2000, 115, 740-745.	0.7	14
64	Molecular characterization of the thermosensitive E1 ubiquitin-activating enzyme cell mutant A31N-ts20. FEBS Journal, 2000, 267, 3712-3722.	0.2	42
65	Antiviral Activity of an Intracellularly Expressed Single-Chain Antibody Fragment Directed against the Murine Leukemia Virus Capsid Protein. Human Gene Therapy, 2000, 11, 389-401.	2.7	8
66	Proteolysis of p53 Protein by Ubiquitous Calpains. , 2000, 144, 297-307.		11
67	Efficient Cell Infection by Moloney Murine Leukemia Virus-Derived Particles Requires Minimal Amounts of Envelope Glycoprotein. Journal of Virology, 2000, 74, 8480-8486.	3.4	24
68	Immunotherapy of a Viral Disease byin VivoProduction of Therapeutic Monoclonal Antibodies. Human Gene Therapy, 2000, 11, 1407-1415.	2.7	30
69	Development of Cellulose Sulfateâ€based Polyelectrolyte Complex Microcapsules for Medical Applications. Annals of the New York Academy of Sciences, 1999, 875, 46-63.	3.8	107
70	Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?. Molecular Biology Reports, 1999, 26, 45-51.	2.3	51
71	Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene, 1998, 17, 327-337.	5.9	44
72	Affinity of recombinant antibody and antibody fragment binding to human thyroglobulin: potential applications in gene therapy. , 1998, 11, 117-118.		0

#	Article	IF	Citations
73	Cell targeting by murine retroviral vectors. Critical Reviews in Oncology/Hematology, 1998, 28, 7-30.	4.4	21
74	Genetically Engineered Antibodies in Gene Transfer and Gene Therapy. Human Gene Therapy, 1998, 9, 2165-2175.	2.7	28
75	In VitroandIn VivoSecretion of Cloned Antibodies by Genetically Modified Myogenic Cells. Human Gene Therapy, 1997, 8, 1219-1229.	2.7	34
76	Decreased susceptibility to calpains of <scp>v</scp>-FosFBR but not of <scp>v</scp>-FosFBJ or <scp>v</scp>-JunASV17 retroviral proteins compared with their cellular counterparts. Biochemical Journal, 1997, 323, 685-692.	3.7	14
77	Towards efficient cell targeting by recombinant retroviruses. Trends in Molecular Medicine, 1997, 3, 396-403.	2.6	9
78	Complex mechanisms for c-fos and c-jun degradation. Molecular Biology Reports, 1997, 24, 51-56.	2.3	49
79	PEST motifs are not required for rapid calpain-mediated proteolysis of c-fos protein. Biochemical Journal, 1996, 313, 245-251.	3.7	54
80	Analysis of the individual contributions of immunoglobulin heavy and light chains to the binding of antigen using cell transfection and plasmon resonance analysis. Journal of Immunological Methods, 1996, 193, 177-187.	1.4	24
81	Cloning and Expression of a Single-Chain Antibody Fragment Specific for a Monomorphic Determinant of Class I Molecules of the Human Major Histocompatibility Complex. Hybridoma, 1995, 14, 443-451.	0.6	8
82	Ubiquitinylation Is Not an Absolute Requirement for Degradation of c-Jun Protein by the 26 S Proteasome. Journal of Biological Chemistry, 1995, 270, 11623-11627.	3.4	139
83	c-fos proto-oncogene regulation and function. Critical Reviews in Oncology/Hematology, 1994, 17, 93-131.	4.4	136
84	Long-term expression of the c-fos protein during the in vitro differentiation of cerebellar granule cells induced by potassium or NMDA. Molecular Brain Research, 1992, 12, 249-258.	2.3	32
85	In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. European Journal of Immunology, 1991, 21, 1759-1762.	2.9	87
86	Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells. European Journal of Immunology, 1990, 20, 409-416.	2.9	7
87	Nuclear localization of c-Fos, but not v-Fos proteins, is controlled by extracellular signals. Cell, 1990, 63, 341-351.	28.9	185
88	Cerebellar granule cell survival and maturation induced by K+ and NMDA correlate with c-fos proto-oncogene expression. Neuroscience Letters, 1989, 107, 55-62.	2.1	60
89	Interferons and oncogenes in the control of cell growth and differentiation : working hypothesis and experimental facts. Biochimie, 1988, 70, 869-875.	2.6	11
90	Role of RNA structures m c-myc and c-fos gene regulations. Gene, 1988, 72, 287-295.	2.2	14

#	ARTICLE	IF	CITATIONS
91	The regulatory strategies of c-myc and c-fos proto-oncogenes share some common mechanisms. Biochimie, 1988, 70, 877-884.	2.6	18
92	Regulation of c-fosgene expression in hamster fibroblasts: initiation and elongation of transcription and mRNA degradation. Nucleic Acids Research, 1987, 15, 5657-5667.	14.5	241
93	c-myc gene regulation still holds its secret. Trends in Genetics, 1987, 3, 47-51.	6.7	52
94	c-myc gene is transcribed at high rate in G0-arrested fibroblasts and is post-transcriptionally regulated in response to growth factors. Nature, 1985, 317, 443-445.	27.8	324
95	Posttranscriptional mechanisms are responsible for accumulation of truncated c-myc RNAs in murine plasma cell tumors. Cell, 1985, 42, 589-597.	28.9	245
96	Characterization of the transcription products of glyceraldehyde 3-phosphate-dehydrogenase gene in HeLa cells. FEBS Journal, 1984, 145, 299-304.	0.2	79
97	Mouse DNA sequences complementary to small nuclear RNA U1. Nucleic Acids Research, 1982, 10, 4627-4640.	14.5	16
98	An easy method for the selection of restriction- and modification-deficient mutants of Escherichia coli K-12. Gene, 1980, 11, 173-175.	2.2	9